好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2026 Annual Meeting | Industry Therapeutic Update from Amgen: Introduction to an Effective NMOSD Treatment with an Established Safety Profile

Saturday 04/18/26
11:45 AM - 12:45 PM CDT Add To Calendar
This program will be presented in-person only
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
Sam Hooshmand, DO
Autoimmune Neurology
Join us for a presentation on an educational overview of neuromyelitis optica spectrum disorder (NMOSD), including relevant aspects of disease pathophysiology, key considerations in treatment strategies, and clinical insights that are shaping current approaches to patient care, including the role of an effective treatment option with an established safety profile.
No CME available
Event Timeline
11:45 AM - 12:45 PM CDT Speaker Industry Therapeutic Update from Amgen: Long Term Maintenance of NMOSD
Faculty Disclosures
Sam Hooshmand, DO Dr. Hooshmand has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genetech USA. Dr. Hooshmand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics . Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genetech USA. Dr. Hooshmand has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Hooshmand has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for TG Therapeutics . Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen . The institution of Dr. Hooshmand has received research support from Novartis .